In 2007, the pharmaceutical company Bayer gave up on a male contraceptive “that involved an annual implant and a quarterly injection,” as my colleague Olga Khazan reported in 2015. The company, she wrote, “concluded that men would consider the regimen—in the words of a spokesperson—‘not as convenient as a woman taking a pill once a day.’

”Well, yes. That is far more convenient—for the men. Women will put up with it, of course, as they have for years, because the stakes are that high. And as research into male birth control accelerates, we are starting to see this hypocrisy more clearly—that the burdens women bear in exchange for their reproductive freedom are considered too much to expect men to deal with.

Source: The Different Stakes of Male and Female Birth Control – The Atlantic